

BCCA Protocol Summary for Topical Therapy for Ocular Malignancies Using Interferon-Alfa-2B Eye Drops

Protocol Code

OCIFN

Tumour Group

Ocular and orbital

Contact Physician

Dr. Jack Rootman

ELIGIBILITY:

- malignant melanoma of the conjunctiva
- ocular surface squamous neoplasia (OSSN), also known as conjunctival-corneal intraepithelial neoplasia (CCIN)

EXCLUSIONS:

- Pre-malignant primary acquired melanosis

TESTS:

- Baseline: biopsy of lesion
- If clinically indicated: incomplete regression

PREMEDICATIONS:

- no antiemetics required

TREATMENT:

Drug	Dose	BCCA Administration Guideline
Interferon-Alfa-2B	1 million units/mL drops, qid for 7-28 days	Topical

- Repeat every 7 days x 2-3 cycles.
- Discontinue if no response after 3 cycles.

PRECAUTIONS:

1. Temporary occlusion of punctum
2. Vasoline barrier on lid to prevent burning

Call Dr. Jack Rootman or tumour group delegate at Eye Care Centre @ (604) 875-4485 with any problems or questions regarding this treatment program.

Date activated: **1 Dec 2009**

Date revised:

References:

1. Schechter BA, Koreishi AF, Karp CL, et al. Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b. *Ophthalmology* 2008;115(8):1291-6.

2. Sturges A, Butt AL, Lai JE, et al. Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia. *Ophthalmology* 2008;115(8):1297-1302.